TGTX earnings / call / takeaways

TGTX Q3 FY26 earnings call: key takeaways

What TGTX said on its earnings call of November 9, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 9, 2026·AI-generated from the call transcript and Lician data

TGTX reported third quarter 2026 revenue of $260 million, exceeding the $245.4 million consensus estimate (14:51)
The company raised its full-year global revenue guidance to $1 billion. (14:51)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	$0.37	–	–
Revenue	$245.4M	–	–

EPS basis: Unverified: no SEC figure to check the provider EPS against

What changed since last quarter

The company raised full-year global revenue guidance to $1 billion, up from previous expectations. (14:51)
The company expects to launch a simplified IV initiation regimen for Briomvi in mid-2027, which could drive additional demand. (18:10)
The company raised U.S. Briomvi net product revenue guidance to $915 to $920 million. (30:20)

Guidance

Metric	This call	Previous call
Revenue	Full-year global revenue guidance of $1 billion (14:51)	not captured
Revenue	U.S. Breonvy net product revenue guidance of $915 to $920 million (30:20)	not captured

What analysts pressed on

Whether the company needs to deepen GrossToNet in 2027 to maintain payer access. (41:56)
Potential impact of 340B policy changes on Briomvi IV revenue. (58:06)

In their words

We're delivering on our commercial commitments, raising our outlook, and building a business that we believe has the potential to become substantially larger than it is today. Mike White (19:56)
We're not starting from scratch. We already have an established brand, a growing physician network. Mike White (18:10)
We believe no both patients should have to choose their treatment solely based on route of administration. Mike White (18:10)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.